PROCEPT BioRobotics (PRCT) Faces Lawsuit Questions As Undervalued Narrative Holds

Simply Wall St.10-08

The latest focus on PROCEPT BioRobotics (PRCT) stems from a fresh securities lawsuit tied to alleged discounting practices and coincides with the appointment of cardiac surgeon Dr. Michael Mack as an ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2673006749?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987","is_english":true,"pubTime":"2026-10-08 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2673006749","market":"sg","top_or_hot":-1,"title":"PROCEPT BioRobotics (PRCT) Faces Lawsuit Questions As Undervalued Narrative Holds","media":"Simply Wall St.","content":"<div>\n<p>The latest focus on PROCEPT BioRobotics (PRCT) stems from a fresh securities lawsuit tied to alleged discounting practices and coincides with the appointment of cardiac surgeon Dr. Michael Mack as an ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/procept-biorobotics-prct-faces-lawsuit-questions-as-underval\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PROCEPT BioRobotics (PRCT) Faces Lawsuit Questions As Undervalued Narrative Holds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPROCEPT BioRobotics (PRCT) Faces Lawsuit Questions As Undervalued Narrative Holds\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-08 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/procept-biorobotics-prct-faces-lawsuit-questions-as-underval><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The latest focus on PROCEPT BioRobotics (PRCT) stems from a fresh securities lawsuit tied to alleged discounting practices and coincides with the appointment of cardiac surgeon Dr. Michael Mack as an ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/procept-biorobotics-prct-faces-lawsuit-questions-as-underval\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CEO","symbol_name":"中海油","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/procept-biorobotics-prct-faces-lawsuit-questions-as-underval","article_id":"2673006749","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/procept-biorobotics-prct-faces-lawsuit-questions-as-underval","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2673006749","pubTimestamp":1791470662,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The latest focus on PROCEPT BioRobotics (PRCT) stems from a fresh securities lawsuit tied to alleged discounting practices and coincides with the appointment of cardiac surgeon Dr. Michael Mack as an independent director.\nFor context, PROCEPT BioRobotics shares trade at US$17.91 after a sharp 30 day share price return decline of 21.31%, contributing to a year to date share price return fall of 41.77% and a 1 year total shareholder return decline of 48.46% as investors react to the lawsuit...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CEO":"中海油","BK4082":"医疗保健设备","PRCT":"PROCEPT BioRobotics","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC"},"translate_title":"PROCEPT BioRobotics (PRCT) 面临诉讼问题，因为被低估的叙述仍然有效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CEO":1,"PRCT":1.5},"content_text":"The latest focus on PROCEPT BioRobotics (PRCT) stems from a fresh securities lawsuit tied to alleged discounting practices and coincides with the appointment of cardiac surgeon Dr. Michael Mack as an independent director. For context, PROCEPT BioRobotics shares trade at US$17.91 after a sharp 30 day share price return decline of 21.31%, contributing to a year to date share price return fall of 41.77% and a 1 year total shareholder return decline of 48.46% as investors react to the lawsuit headlines and boardroom changes while reassessing longer term risks and potential. Contrast PROCEPT BioRobotics' legal and governance stress test with other potential opportunities by scanning our hand picked 31 resilient stocks with low risk scores, which aim to keep business risk scores in check. After a steep reset that leaves PROCEPT BioRobotics at US$17.91 and facing both a lawsuit and fresh oversight, are investors now paying for past optimism, or still getting meaningful upside on today’s valuation? AdvertisementMost Popular Narrative: 70% Undervalued Against PROCEPT BioRobotics' last close at $17.91, the most followed narrative on Simply Wall St anchors fair value closer to $60, which frames the recent selloff as far more severe than that valuation story suggests. I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense. The sell side analyst who chased the share price up to highs in 2024 (when the price was way too frothy) are doing the same thing now by revising the share price lower and lower, when clearly the company is still doing a great job. The recent downgrade by Leerink, citing PAE as a possible headwind for PRCT growth, is in direct opposition to what Larry Wood (CEO) stated at the last earnings call. To quote Larry Wood, “I don’t think PAE is a headwind for us at all. I think PAE is a big red herring. It’s a procedure that really does not get performed in any volume in Europe. And the reason it doesn’t get performed is because it doesn’t get paid for because it’s not a very good procedure.” So if you believe Larry Wood, then the company has been grossly oversold and looks very very cheap down here. If PRCT hit the Q2 numbers watch all the sheep suddenly revise their target prices back up again. I think fair value is still up at $47. PRCT had a reassessment of how to report handpiece sales versus procedures and therefore there was a shortfall on revenue. Clearly they could have stuck with the old model and revenue would have been better. Larry is doing a great job of making reporting a direct reflection of procedures being done. If the numbers are delivered, watch this thing fly. See why 6 investors see PROCEPT BioRobotics as 70% undervalued. Result: Fair Value of $60 (UNDERVALUED) Still, two things could puncture that 70% undervalued story quickly: the outcome of the new lawsuit and any hit to PROCEPT BioRobotics' urology demand narrative. Find out about the key risks to this PROCEPT BioRobotics narrative. Another View On PROCEPT BioRobotics' Valuation That $60 fair value narrative paints PROCEPT BioRobotics as deeply undervalued. A different lens tells a cooler story. On a P/S of roughly 3x, the stock trades above the US Medical Equipment industry at 2.6x but around its own fair ratio of 3x, which points to limited valuation cushion if sentiment sours. Investors weighing that premium against industry peers might ask whether the story here is mispricing or simply higher expectations baked into the current tag, and what would really need to change for that gap to widen. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:PRCT P/S Ratio as at Oct 2026Next Steps Reading this mix of concern and optimism around PROCEPT BioRobotics, you should move quickly, scrutinise the full data set yourself, then weigh the 1 key reward and 1 important warning sign. Looking For More Investment Ideas Beyond PROCEPT BioRobotics? If PROCEPT BioRobotics has you rethinking risk, use this moment to widen your watchlist with a few focused stock idea sets built around clear filters.  Target stability first by scanning a list of solid balance sheet and fundamentals (25 results) to help you focus on businesses with stronger financial footing than the broader market. Hunt for mispriced opportunities through the 29 high quality undervalued stocks and see which companies trade on numbers that look disconnected from their fundamentals. Build a cash flow stream by reviewing the 8 dividend fortresses and identify income ideas that could complement higher risk growth positions in your portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2673006749","isCrawlerRequest":true}